Cohen Lawrence B continued to hold its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 600 shares of the biopharmaceutical company’s stock at the end of the second quarter. Cohen Lawrence B’s holdings in Regeneron Pharmaceuticals were worth $295,000 at the end of the most recent quarter.
Other large investors have also recently added to or reduced their stakes in the company. Alpha Windward LLC boosted its stake in Regeneron Pharmaceuticals by 0.3% in the second quarter. Alpha Windward LLC now owns 384 shares of the biopharmaceutical company’s stock worth $189,000 after buying an additional 1 shares during the period. Concert Wealth Management Inc. boosted its stake in Regeneron Pharmaceuticals by 0.4% in the first quarter. Concert Wealth Management Inc. now owns 723 shares of the biopharmaceutical company’s stock worth $269,000 after buying an additional 3 shares during the period. Cleararc Capital Inc. boosted its stake in Regeneron Pharmaceuticals by 0.3% in the first quarter. Cleararc Capital Inc. now owns 1,850 shares of the biopharmaceutical company’s stock worth $717,000 after buying an additional 5 shares during the period. Sheaff Brock Investment Advisors LLC boosted its stake in Regeneron Pharmaceuticals by 1.4% in the first quarter. Sheaff Brock Investment Advisors LLC now owns 750 shares of the biopharmaceutical company’s stock worth $291,000 after buying an additional 10 shares during the period. Finally, Grandfield & Dodd LLC boosted its stake in Regeneron Pharmaceuticals by 1.1% in the first quarter. Grandfield & Dodd LLC now owns 1,497 shares of the biopharmaceutical company’s stock worth $580,000 after buying an additional 17 shares during the period. Institutional investors own 66.89% of the company’s stock.
Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ REGN) traded down 1.70% during midday trading on Tuesday, reaching $512.38. 251,251 shares of the company’s stock traded hands. The company has a 50 day moving average of $495.83 and a 200 day moving average of $415.60. Regeneron Pharmaceuticals, Inc. has a 52-week low of $325.35 and a 52-week high of $543.55. The firm has a market cap of $54.09 billion, a PE ratio of 62.02 and a beta of 1.67.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported $2.92 earnings per share for the quarter, beating analysts’ consensus estimates of $2.50 by $0.42. Regeneron Pharmaceuticals had a net margin of 19.34% and a return on equity of 22.99%. The firm had revenue of $1.32 billion for the quarter, compared to analyst estimates of $1.30 billion. During the same period last year, the firm earned $2.57 earnings per share. The business’s quarterly revenue was up 9.8% compared to the same quarter last year. On average, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post $12.80 EPS for the current fiscal year.
WARNING: “Regeneron Pharmaceuticals, Inc. (REGN) Position Held by Cohen Lawrence B” was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The correct version of this report can be read at https://stocknewstimes.com/2017/07/25/regeneron-pharmaceuticals-inc-regn-position-held-by-cohen-lawrence-b.html.
A number of equities research analysts have issued reports on the stock. UBS AG set a $489.00 price target on shares of Regeneron Pharmaceuticals and gave the company a “buy” rating in a report on Friday, May 5th. BMO Capital Markets increased their target price on shares of Regeneron Pharmaceuticals from $412.00 to $421.00 and gave the company a “hold” rating in a research note on Monday, May 15th. Piper Jaffray Companies increased their target price on shares of Regeneron Pharmaceuticals from $446.00 to $557.00 and gave the company an “overweight” rating in a research note on Tuesday, June 20th. Cowen and Company reiterated a “hold” rating and issued a $380.00 target price on shares of Regeneron Pharmaceuticals in a research note on Monday, May 15th. Finally, Sanford C. Bernstein reiterated an “outperform” rating on shares of Regeneron Pharmaceuticals in a research note on Thursday, May 25th. One equities research analyst has rated the stock with a sell rating, sixteen have assigned a hold rating and thirteen have issued a buy rating to the company. Regeneron Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $467.38.
In other news, major shareholder Sanofi bought 136,050 shares of the stock in a transaction dated Friday, June 2nd. The stock was bought at an average price of $478.17 per share, for a total transaction of $65,055,028.50. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Michael S. Aberman sold 2,269 shares of the stock in a transaction dated Thursday, June 22nd. The shares were sold at an average price of $532.42, for a total transaction of $1,208,060.98. Following the completion of the sale, the senior vice president now owns 9,193 shares of the company’s stock, valued at approximately $4,894,537.06. The disclosure for this sale can be found here. Insiders sold 59,396 shares of company stock worth $28,484,734 over the last ninety days. Insiders own 10.40% of the company’s stock.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
